Drugs / PRV211
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05893888 | Nov 2024 → Oct 2026 expected | oral cavity squamous cell carcinoma | Privo Technologies | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRV211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05893888 ↗ |
| Route | Topical | “The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area.” NCT05893888 ↗ |